Why AIThalassemia Matters
Thalassemia is an inherited blood disorder caused by defects in the genes that control hemoglobin production. Many carriers have no symptoms, yet two carriers have a 25 % chance of having a child with severe thalassemia.
Early identification of carriers is therefore essential.
Comprehensive screening programmes, such as the premarital initiative in Cyprus, have reduced the incidence of thalassemia by 95 %.
AIThalassemia builds on this success with an AI‑driven approach to make carrier screening affordable, efficient and scalable.
AI-enhanced thalassemia screening for everyone
Easy-to-use
Works with existing CBC/DCIP – no new equipment required
Cost-effective
$5 per test – economical compared to molecular testing
Fast results
Preliminary results in under 5 hours for fast decision-making
Reliable
$9.8% sensitivity (validated on 70,000+ samples)
Key Benefits for Hospitals and Laboratories
Early, accurate identification of carriers – Our algorithm analyses routine complete blood count (CBC)
results, focusing on mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and
red‑blood‑cell (RBC) count. Studies show beta‑thalassemia carriers typically have an MCV around 62 fL,
MCH about 19.7 pg and an elevated RBC count (~5.3 × 109/L compared with 4.7 × 109/L in
non‑carriers). By recognising these patterns, we flag potential carriers with high sensitivity.
Reduced reliance on costly confirmatory tests – Confirming beta‑thalassemia requires
hemoglobin A2 quantification via HPLC or capillary electrophoresis. These tests are expensive
and not widely available, and performing them on every suspected individual burdens lab budgets
and staff. Our platform pre‑screens using inexpensive CBC data (MCV < 80 fL or MCH < 27 pg), so
only high‑risk samples proceed to confirmatory testing.
This saves time and money without compromising care.
Fast integration and minimal training – AIThalassemia integrates seamlessly with existing
Laboratory Information Systems (LIS) or Electronic Medical Records (EMR). Staff simply upload
CBC results; our engine returns a risk category and recommendations. Minimal training is
required, and we offer full support during onboarding.
Key Benefits for Hospitals and Laboratories
Improved outcomes and population health – Early detection enables carriers to receive
genetic counselling and make informed reproductive choices. National programmes
demonstrate how screening and counselling can virtually eliminate severe thalassemia
births and reduce the need for lifelong transfusions and iron‑chelation therapy
Evidence‑based and transparent – The AI model is built on peer‑reviewed
data and uses established red‑cell indices such as the Mentzer and
Shine–Lal indices. We continuously refine the model with local data while
maintaining high specificity.
Secure and compliant – Patient data are anonymised before processing. We comply with
GDPR, HIPAA and local data‑protection laws, ensuring confidentiality and privacy.
Partner With Us
AIThalassemia is already partnering with clinics and laboratories to pilot AI‑driven carrier screening.
We invite hospitals and national programmes to join us.
Together we can reduce thalassemia incidence, improve patient care and control costs.
Contact us today to arrange a demonstration or request a proposal.